Good to see they are acknowledging the issues of CBD with...

Good to see they are acknowledging the issues of CBD with bioavailability highlighted previously. Dermatology has very low reimbursement in US so despite potential for a lot of precriptions the ROI is hard to follow especially with so many unapproved CBD products available, FDA has somewhat said they are unable to enforce. A new drug that could be patentable is a new therapy area would be good but also sets up a longer to market situation, they have lost their first mover status and now several competitors are in the race especially in other therapy areas. It’s becoming much more and execution story versus a novel product story. With leadership team based solely in Dermatology space I would expect they need to bring on people that can assist in other areas in order to capitalize on the opportunity.